Mesoblast (ASX:MSB) Reports US$115M First-Year RYONCIL Revenue as Cell-Therapy Launch Advances

Aditi Sarkar

13 August 2026 12:10 PM AEST

Mesoblast (ASX:MSB) Reports US$115M First-Year RYONCIL Revenue as Cell-Therapy Launch Advances

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Mesoblast reported US$115 million in net Revenue from the first full year of RYONCIL commercial sales.
Fourth-quarter RYONCIL revenue reached US$36 million, with second-half revenue of US$66.5 million.
The company is progressing adult steroid-refractory acute graft-versus-host disease trials to expand the RYONCIL opportunity.
Mesoblast reported US$103 million in cash at the end of the reporting period after drawing US$50 million from an existing Credit facility.

Mesoblast (ASX:MSB) has completed the first full year of commercial sales for RYONCIL, reporting US$115 million in net revenue since the cell therapy received U.S. approval.

The company reported fourth-quarter revenue of US$36 million in its 30 July 2026 update, with second-half revenue reaching US$66.5 million as sales increased through the year.

RYONCIL, known generically as remestemcel-L, is approved in the United States for treating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children, a serious complication that can occur following bone marrow transplantation.

Alongside commercial progress, Mesoblast (ASX:MSB) outlined continued development across its broader mesenchymal stromal cell platform, including programs targeting adult GvHD, chronic low back pain, heart failure and Duchenne muscular dystrophy.

What Was Announced?

Mesoblast reported RYONCIL net revenue of US$36 million for the fourth quarter of FY2026 and US$115 million for the first full year of commercial sales following FDA approval.

RYONCIL is currently approved for pediatric SR-aGvHD, where a transplant recipient's immune system attacks healthy tissues and does not respond adequately to steroid treatment.

The company is now progressing an adult SR-aGvHD registration trial, targeting a significantly larger patient population. Mesoblast expects around 40 U.S. transplant centres to participate, covering an estimated 60% of approximately 8,500 adult allogeneic bone marrow transplants performed annually in the country.

Beyond RYONCIL, Mesoblast reported progress across its pipeline. Rexlemestrocel-L reached target enrolment of more than 300 patients in a Phase 3 chronic low back pain trial.

The company also received a Biologics License Application filing number related to preventing gastrointestinal bleeding in heart failure patients using left ventricular assist devices (LVADs).

Mesoblast received FDA clearance for an Investigational New Drug (IND) application to begin a registrational trial of its cell therapy in ambulatory children aged five to nine with Duchenne muscular dystrophy.

The company also acquired an exclusive worldwide licence for a chimeric antigen receptor (CAR) platform designed to enhance mesenchymal stromal cells for inflammatory and autoimmune conditions.

Why This Matters

For Mesoblast (ASX:MSB), RYONCIL's commercial performance provides early information on adoption of a cell therapy product in the U.S. market.

Cell therapies involve complex manufacturing, logistics and reimbursement considerations compared with conventional medicines. Continued revenue growth through the launch period provides visibility into hospital adoption and commercial execution.

The adult SR-aGvHD expansion remains an important future opportunity because the adult transplant population is substantially larger than the current pediatric indication.

A successful expansion could increase the addressable market for RYONCIL without requiring development of a separate product.

Company Background

Mesoblast is a dual-listed regenerative medicine company developing therapies based on allogeneic mesenchymal stromal cells derived from donor tissue.

RYONCIL is the company's first FDA-approved product and is currently indicated for pediatric SR-aGvHD.

The company is also developing rexlemestrocel-L across multiple indications, including chronic low back pain and heart failure-related complications.

Additional programs include a Duchenne muscular dystrophy trial and a CAR-enhanced cell therapy platform targeting inflammatory and autoimmune diseases.

Financial Position

Mesoblast reported US$103 million in cash at the end of the reporting period after drawing US$50 million from an existing credit facility.

Full-year operating cash expenditure was US$43.8 million, and the company estimated its available funding position supported approximately 11.1 additional quarters of operations at current spending levels.

The company continues to rely on RYONCIL commercial revenue growth, available cash resources and financing arrangements to support ongoing development activities.

What Comes Next?

Key upcoming milestones for Mesoblast (ASX:MSB) include further activation of U.S. sites for the adult SR-aGvHD registration trial, progression of the chronic low back pain Phase 3 program and advancement of the LVAD-related regulatory pathway.

The company also expects to begin enrolment in the Duchenne muscular dystrophy registrational trial following FDA clearance.

Further development of the recently licensed CAR-enhanced mesenchymal stromal cell platform will be required before potential clinical applications in inflammatory bowel disease and lupus nephritis.

Risks

Mesoblast (ASX:MSB) remains exposed to clinical, regulatory and commercial execution risks across multiple programs. Expansion of RYONCIL into adult SR-aGvHD depends on successful clinical outcomes and regulatory decisions. Cell therapy manufacturing, reimbursement and hospital adoption can involve additional complexity compared with conventional medicines. The company also relies on continued RYONCIL revenue growth and available funding resources, while further Capital requirements remain possible if development costs increase.

Investor Takeaway

Mesoblast has reported US$115 million in first-year RYONCIL revenue, providing early visibility into commercial adoption of its first approved cell therapy product.

The adult SR-aGvHD expansion program represents a larger potential application, while the broader pipeline provides additional development opportunities across multiple medical areas.

However, Mesoblast continues to manage several concurrent clinical and regulatory programs, and future progress will depend on execution, funding management and successful expansion of its cell therapy platform.

FAQs

Q: What is RYONCIL?

A:RYONCIL is Mesoblast's allogeneic cell therapy approved in the United States for pediatric steroid-refractory acute graft-versus-host disease.

Q: How much revenue did Mesoblast report from RYONCIL?

A:Mesoblast reported US$115 million in net revenue during the first full year of commercial sales.

Q: What is Mesoblast's adult SR-aGvHD program?

A:The program is evaluating RYONCIL in adults with steroid-refractory acute graft-versus-host disease.

Q: What other therapies is Mesoblast developing?

A:Mesoblast is developing programs targeting chronic low back pain, heart failure complications, Duchenne muscular dystrophy and inflammatory conditions.

Q: How much cash did Mesoblast report?

A:Mesoblast reported US$103 million in cash at the end of the reporting period.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.